4.41
-0.07(-1.56%)
Currency In USD
| Previous Close | 4.48 |
| Open | 4.51 |
| Day High | 4.53 |
| Day Low | 4.39 |
| 52-Week High | 11.78 |
| 52-Week Low | 3.9 |
| Volume | 16,655 |
| Average Volume | 44,488 |
| Market Cap | 50.24M |
| PE | -1.45 |
| EPS | -3.05 |
| Moving Average 50 Days | 5.33 |
| Moving Average 200 Days | 6.48 |
| Change | -0.07 |
If you invested $1000 in Nutriband Inc. (NTRB) since IPO date, it would be worth $768.29 as of January 07, 2026 at a share price of $4.41. Whereas If you bought $1000 worth of Nutriband Inc. (NTRB) shares 3 years ago, it would be worth $1,185.48 as of January 07, 2026 at a share price of $4.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
GlobeNewswire Inc.
Dec 29, 2025 2:00 PM GMT
Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the
Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum TechnologyORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadeq